Retatrutide has moved beyond early-stage clinical research into a broad Phase 3 development program. Results reported in 2026 have increased scientific interest because multiple trials have reported substantial changes in body weight and other metabolic measures. But Phase 3 results still need to be interpreted carefully. Some 2026 findings have been released as topline company results and are awaiting detailed peer-reviewed publication. Retatrutide also remains investigation

Retatrutide has attracted significant attention because early clinical research produced substantial changes in body weight. Understanding those results requires looking at how the trial was designed, who participated, what researchers measured, and what the study could not establish. The pivotal Phase 2 study was a randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine. It evaluated retatrutide in 338 adults with obesity or overwe

Retatrutide has become one of the most closely watched investigational compounds in metabolic research. Much of the attention comes from its unusual mechanism: instead of targeting only one hormone receptor, retatrutide activates three — GIP, GLP-1 and glucagon receptors. That makes the question “How is retatrutide different from a GLP-1?” particularly important. The answer is not simply that it is a stronger GLP-1. Retatrutide is a different type of multi-receptor agonist be

5-Amino-1MQ has attracted attention in metabolic and longevity research because it targets an enzyme called nicotinamide N-methyltransferase (NNMT). NNMT is involved in the metabolism of nicotinamide and can influence cellular methylation and NAD+ metabolism. Researchers have therefore investigated whether inhibiting NNMT could alter metabolic pathways involved in obesity, insulin sensitivity, cellular energy metabolism and aging. 5-Amino-1MQ is one of several small-molecule

KPV research explained in plain language, including its biological origins, anti-inflammatory research, intestinal and skin studies, human evidence, safety questions, and what researchers still don't know. KPV is a small tripeptide that has attracted interest in experimental research involving inflammation, intestinal biology, skin biology and cellular signaling. The name KPV refers to the three amino acids lysine-proline-valine. KPV is also the C-terminal portion of α-melano

A laboratory research scene featuring NAD+ (nicotinamide adenine dinucleotide), scientific equipment, molecular imagery, and visual references to cellular energy, metabolism, DNA repair, aging research, and human studies.

TB-500 and thymosin beta-4 peptide research in a laboratory setting

Retatrutide research explained in plain language, including how the triple-agonist works, what clinical trials have found, safety findings, and what researchers still don't know. Retatrutide has become one of the most closely watched investigational medicines in metabolic research. Unlike medications that primarily target one or two metabolic hormone receptors, retatrutide is designed to activate three receptors: GIP, GLP-1 and glucagon. Researchers are studying whether this

BPC-157 research explained in plain language, including preclinical studies, limited human research, safety questions, and what scientists still don't know. BPC-157 has attracted significant attention in recent years, particularly in research involving tissue repair, inflammation, gastrointestinal biology and musculoskeletal injuries. But there is an important distinction between interesting research findings and established medical evidence. Much of the research involving BP